Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilazapril. A review.

T Szucs1

  • 1F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Drugs
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Cilazapril, a novel angiotensin converting enzyme (ACE) inhibitor, effectively lowers blood pressure in diverse patient groups. It demonstrates a favorable tolerability profile and may also moderate vascular proliferation post-injury.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear Astrophysics in the Storage Ring: Background Suppressed Simultaneous Measurement of (p,γ) and (p,n) Reactions.

Physical review letters·2025
Same author

First Direct Measurement of the 64.5 keV Resonance Strength in the ^{17}O(p,γ)^{18}F Reaction.

Physical review letters·2024
Same author

Proton-Capture Rates on Carbon Isotopes and Their Impact on the Astrophysical ^{12}C/^{13}C Ratio.

Physical review letters·2023
Same author

Direct Measurement of the ^{13}C(α,n)^{16}O Cross Section into the s-Process Gamow Peak.

Physical review letters·2021
Same author

The baryon density of the Universe from an improved rate of deuterium burning.

Nature·2020
Same author

Successful Prediction of Total α-Induced Reaction Cross Sections at Astrophysically Relevant Sub-Coulomb Energies Using a Novel Approach.

Physical review letters·2020
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
Same journal

Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Design

Background:

  • Cilazapril is a novel nonthiol angiotensin converting enzyme (ACE) inhibitor.
  • It was developed using computer-modeling for high enzyme specificity and selectivity.
  • ACE inhibitors are crucial in managing hypertension and related cardiovascular conditions.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of cilazapril in hypertensive patients.
  • To assess cilazapril's effects in special populations, including the elderly and renally impaired.
  • To investigate cilazapril's potential role in moderating vascular proliferative responses.

Main Methods:

  • Clinical investigations involving over 4000 patients with varying degrees of hypertension.
  • Studies included special patient groups with comorbidities like congestive cardiac failure or COPD.

Related Experiment Videos

  • Comparative tolerability assessments against established antihypertensive medications were performed.

    • Main Results:

    • A single daily dose of cilazapril demonstrated a clear blood pressure-lowering effect.
    • The tolerability of cilazapril was comparable to other commonly prescribed antihypertensives.
    • Emerging evidence suggests cilazapril may mitigate post-vascular injury proliferation.

    Conclusions:

    • Cilazapril is an effective antihypertensive agent with a well-established blood pressure-lowering capacity.
    • Its tolerability profile supports its use as a viable treatment option.
    • Further clinical studies are underway to confirm its potential benefits in vascular remodeling.